NCT06389292 - A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | Biotech Hunter

Enrollment

486

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

May 25, 2028

Study Completion Date

March 26, 2029

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

APG-2575(Lisaftoclax )

QD, oral administration, every 28 days for a dosing cycle.

OTHER

Placebo

QD, oral administration, every 28 days for a dosing cycle.

DRUG

Azacitidine Injection

QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.

Trial Locations (6)

RECRUITING

"Moscow Multidisciplinary Clinical Center Kommunarka", Moscow

RECRUITING

Botkin Moscow Multidisciplinary Research and Clinical Center, Moscow

RECRUITING

Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency, Saint Petersburg

RECRUITING

Leningrad Regional Clinical Hospital, Saint Petersburg

RECRUITING

Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou